OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
OPK - OPKO Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$3.13
DETAILS
HIGH:
$4.00
LOW:
$2.25
MEDIAN:
$3.12
CONSENSUS:
$3.13
UPSIDE:
92.02%
Stock News
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
Comparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)
Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Ardent Health and
OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated “Hold” by Sell-Side Analysts
Shares of OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Analyzing HCA Healthcare (NYSE:HCA) & OPKO Health (NASDAQ:OPK)
HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares HCA Healthcare
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
Connor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPK
Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in the undefined quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 shares of the biotechnology company's stock, valued at approximately $618,000. Connor Clark and Lunn Investment Management
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Price Targets
Opko Health (OPK) PT Raised to $4 at Piper Sandler
$4.00
(was $1.62)
UBS
Opko Health upgraded to Outperform from Market Perform at Barrington
$2.25
(was $1.61)
Barrington
Opko Health downgraded to Hold from Buy at Jefferies
$1.60
(was $1.46)
Jefferies
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
$3.00
(was $1.70)
Yi Chen
·
H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On OPKO Health with Buy Rating, Announces Price Target of $3
$3.00
(was $1.29)
H.C. Wainwright
Opko Health price target lowered to $4 from $5 at Piper Sandler
$4.00
(was $2.40)
Edward Tenthoff
·
Piper Sandler